131 related articles for article (PubMed ID: 38589004)
21. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
Bagheri E; Alibolandi M; Abnous K; Taghdisi SM; Ramezani M
J Mater Chem B; 2021 Feb; 9(5):1351-1363. PubMed ID: 33447840
[TBL] [Abstract][Full Text] [Related]
22. A Novel pH-Responsive Iron Oxide Core-Shell Magnetic Mesoporous Silica Nanoparticle (M-MSN) System Encapsulating Doxorubicin (DOX) and Glucose Oxidase (Gox) for Pancreatic Cancer Treatment.
Qi G; Shi G; Wang S; Hu H; Zhang Z; Yin Q; Li Z; Hao L
Int J Nanomedicine; 2023; 18():7133-7147. PubMed ID: 38054080
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes.
Jia L; Shen J; Li Z; Zhang D; Zhang Q; Liu G; Zheng D; Tian X
Int J Pharm; 2013 Mar; 445(1-2):12-9. PubMed ID: 23384728
[TBL] [Abstract][Full Text] [Related]
24. Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer.
Tarannum M; Holtzman K; Dréau D; Mukherjee P; Vivero-Escoto JL
J Control Release; 2022 Jul; 347():425-434. PubMed ID: 35569588
[TBL] [Abstract][Full Text] [Related]
25. Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview.
Slapak EJ; El Mandili M; Bijlsma MF; Spek CA
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214121
[TBL] [Abstract][Full Text] [Related]
26. Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment.
Martínez-Carmona M; Lozano D; Colilla M; Vallet-Regí M
Acta Biomater; 2018 Jan; 65():393-404. PubMed ID: 29127069
[TBL] [Abstract][Full Text] [Related]
27. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
[TBL] [Abstract][Full Text] [Related]
28. Unsaturated nitrogen-rich polymer poly(l-histidine) gated reversibly switchable mesoporous silica nanoparticles using "graft to" strategy for drug controlled release.
Mu S; Liu Y; Wang T; Zhang J; Jiang D; Yu X; Zhang N
Acta Biomater; 2017 Nov; 63():150-162. PubMed ID: 28873341
[TBL] [Abstract][Full Text] [Related]
29. Sugar-decorated mesoporous silica nanoparticles as delivery vehicles for the poorly soluble drug celastrol enables targeted induction of apoptosis in cancer cells.
Niemelä E; Desai D; Nkizinkiko Y; Eriksson JE; Rosenholm JM
Eur J Pharm Biopharm; 2015 Oct; 96():11-21. PubMed ID: 26184689
[TBL] [Abstract][Full Text] [Related]
30. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
31. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
[TBL] [Abstract][Full Text] [Related]
32. Functionalized Mesoporous Silica Nanoparticles for Drug-Delivery to Multidrug-Resistant Cancer Cells.
Igaz N; Bélteky P; Kovács D; Papp C; Rónavári A; Szabó D; Gácser A; Kónya Z; Kiricsi M
Int J Nanomedicine; 2022; 17():3079-3096. PubMed ID: 35859731
[TBL] [Abstract][Full Text] [Related]
33. Enzyme-induced and tumor-targeted drug delivery system based on multifunctional mesoporous silica nanoparticles.
Cheng YJ; Luo GF; Zhu JY; Xu XD; Zeng X; Cheng DB; Li YM; Wu Y; Zhang XZ; Zhuo RX; He F
ACS Appl Mater Interfaces; 2015 May; 7(17):9078-87. PubMed ID: 25893819
[TBL] [Abstract][Full Text] [Related]
34. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
35. Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance.
Jia L; Li Z; Shen J; Zheng D; Tian X; Guo H; Chang P
Int J Pharm; 2015 Jul; 489(1-2):318-30. PubMed ID: 25956050
[TBL] [Abstract][Full Text] [Related]
36. Optical imaging and anticancer chemotherapy through carbon dot created hollow mesoporous silica nanoparticles.
Kang MS; Singh RK; Kim TH; Kim JH; Patel KD; Kim HW
Acta Biomater; 2017 Jun; 55():466-480. PubMed ID: 28373086
[TBL] [Abstract][Full Text] [Related]
37. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo.
Zhang B; Luo Z; Liu J; Ding X; Li J; Cai K
J Control Release; 2014 Oct; 192():192-201. PubMed ID: 25034575
[TBL] [Abstract][Full Text] [Related]
38. Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release.
Hu X; Wang Y; Peng B
Chem Asian J; 2014 Jan; 9(1):319-27. PubMed ID: 24115568
[TBL] [Abstract][Full Text] [Related]
39. Meta-Analysis of Efficacy of Chemotherapy Delivered by Mesoporous Silica Nanoparticles to Tumor-Bearing Mice.
McGoron A
Crit Rev Biomed Eng; 2020; 48(6):327-418. PubMed ID: 33641279
[TBL] [Abstract][Full Text] [Related]
40. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.
Castillo RR; Lozano D; González B; Manzano M; Izquierdo-Barba I; Vallet-Regí M
Expert Opin Drug Deliv; 2019 Apr; 16(4):415-439. PubMed ID: 30897978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
